diazoxide 50 MG/ML Oral Suspension [Proglycem]

Verify with CMS →

diazoxide

RxCUI: 207634

Important: Drug coverage and costs vary by plan and location. Verify coverage directly with your Medicare plan before filling a prescription. This is informational data only and should not replace advice from your healthcare provider or pharmacist.
0%
Plan Coverage
2
Plans Covering
T1
Avg Tier
0%
Prior Auth Required

What the CMS Formulary Data Shows for diazoxide 50 MG/ML Oral Suspension [Proglycem]

Per the CMS 2026 Part D formulary file, diazoxide 50 MG/ML Oral Suspension [Proglycem] (RxNorm concept RXCUI 207634, generic name diazoxide) appears on 1 distinct formulary file spanning 2 Medicare Part D plan offerings - 0% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 1, with a cross-plan average of Tier 1.

Real-world access to diazoxide 50 MG/ML Oral Suspension [Proglycem] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 525 Part D beneficiaries filled diazoxide 50 MG/ML Oral Suspension [Proglycem] in 2023, with total plan-and-beneficiary spending of $2,565,297 and an average per-beneficiary annual cost of $4,886.28. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry diazoxide 50 MG/ML Oral Suspension [Proglycem] today.

Coverage Details

Formularies covering
1
Plans covering
2
Coverage rate
0%
Tier range
Tier 1, Preferred Generic
Average tier
Tier 1, Preferred Generic

Restrictions

Prior authorization required
0% of formularies
Step therapy required
0% of formularies
Quantity limits
0% of formularies

2023 Medicare Spending

Beneficiaries
525
Total spending
$2,565,297
Avg per beneficiary
$4,886.28

Tier Distribution Across Plans

2 plans
Tier 1, Preferred Generic

Medicare Advantage Plans (MA-PD) Covering diazoxide 50 MG/ML Oral Suspension [Proglycem]

2 Medicare Advantage plans with Part D drug coverage include this drug.

Plan Insurer Tier PA Premium States
Hamaspik Medicare Choice (HMO D-SNP) HAMASPIK, INC. T1 No $0 NY
Hamaspik Medicare Select (HMO D-SNP) HAMASPIK, INC. T1 No $34.50 NY

Frequently Asked Questions

Is diazoxide 50 MG/ML Oral Suspension [Proglycem] covered by Medicare Part D?

Yes, diazoxide 50 MG/ML Oral Suspension [Proglycem] is covered by 2 Medicare Part D plans (0% of all Part D formularies).

What tier is diazoxide 50 MG/ML Oral Suspension [Proglycem] on Medicare Part D plans?

diazoxide 50 MG/ML Oral Suspension [Proglycem] averages Tier 1 across Part D plans, ranging from Tier 1 to Tier 1.

Does diazoxide 50 MG/ML Oral Suspension [Proglycem] require prior authorization?

0% of Part D formularies require prior authorization for diazoxide 50 MG/ML Oral Suspension [Proglycem]. Step therapy: 0%. Quantity limits: 0%.

How much does Medicare spend on diazoxide 50 MG/ML Oral Suspension [Proglycem]?

In 2023, total Medicare Part D spending on diazoxide 50 MG/ML Oral Suspension [Proglycem] was $2,565,297, covering 525 beneficiaries. The average spend per beneficiary was $4,886.28.

Data sourced from the Centers for Medicare & Medicaid Services (CMS). See our methodology for details. Retrieved and formatted by PlainMedicare Editorial